1. Unique Effect of Nebivolol on Coronary Hemodynamics: It’s All a Matter of Flow

   • Eli I. Lev
   • Alexander Battler

   Editorial 07 April 2007 Pages: 75 - 76

2. Cerebrovascular Events After Discontinuation of Rofecoxib Treatment

   • Frank Andersohn

   Editorial 03 April 2007 Pages: 77 - 79

3. Statin Pleiotropy: A Popular Concept but Clinical Significance Unclear

   • Jennifer G. Robinson
   • Helmut Schrott

   Editorial 07 April 2007 Pages: 81 - 83

   

4. Effect of β-Blockers on β₃-Adrenoceptor Expression in Chronic Heart Failure

   • Qiang Zhao
   • Tong-Guo Wu
   • Le-Xin Wang

   OriginalPaper 18 April 2007 Pages: 85 - 90

   

5. The Effect of Aggressive Versus Conventional Lipid-lowering Therapy on Markers of Inflammatory and Oxidative Stress

   • Douwe J. Mulder
   • Paul L. van Haelst
   • Jasper J. van Doormaal

   OriginalPaper Open access 07 March 2007 Pages: 91 - 97

   

6. Does the β-Blocker Nebivolol Increase Coronary Flow Reserve?

   • Mario Togni
   • Francesco Vigorito
   • Otto M. Hess

   Clinical Pharmacology and Drug Studies 26 January 2007 Pages: 99 - 108

7. Inverse Relationship between Lipid-lowering Drugs and Saturated Fat Intake in US Adults

   • Devin M. Mann
   • Sundar Natarajan

   OriginalPaper 20 March 2007 Pages: 109 - 115

   

8. Long-term Risk of Ischemic Stroke Associated with Rofecoxib

   • Jonathan Afilalo
   • Michael J. Coussa-Charley
   • Mark J. Eisenberg

   ReviewPaper 28 March 2007 Pages: 117 - 120

9. Pharmacogenomics of Renin Angiotensin System Inhibitors in Coronary Artery Disease

   • James P. Tsikouris
   • Michael J. Peeters

   Review 08 May 2007 Pages: 121 - 132

10. Advertising Campaigns of Sterol-Enriched Food. An Often Neglected Cause of Reduced Compliance to Lipid Lowering Drug Therapy

    • Alevizos Alevizos
    • Constantinos Mihas
    • Anargiros Mariolis

    Letter to the Editor 15 March 2007 Pages: 133 - 134